Slowing CKD Progression

If you have been told your kidney function is declining, here is the most important thing to understand first: chronic kidney disease (CKD) is slowable now in ways it simply was not a decade ago. For most of the twentieth century, doctors could control your blood pressure and blood sugar and then essentially watch the eGFR number drift downward, hoping to delay dialysis by a few years. Today there is a genuine toolkit — several classes of medicine, backed by large, high-quality trials, that measurably slow the loss of kidney function, and in many people flatten the curve enough that they never reach dialysis in their lifetime. This page walks you through each tool in plain language: what it does, why it works, what to expect (including one surprising thing that looks like bad news but is actually good), and the questions worth bringing to your next appointment. None of this replaces your own nephrologist — it is meant to help you have a smarter conversation with them.

The Big Picture: A Slowable Disease
Blood Pressure Control: The Foundation
RAAS Blockade: ACE Inhibitors & ARBs
SGLT2 Inhibitors: The Game-Changer
Finerenone: A New Kind of Protection
GLP-1 Receptor Agonists: The Newest Evidence
Fixing the Downstream Problems
Avoiding Nephrotoxins & Sick-Day Rules
Lifestyle: Smoking, Weight & Exercise
What to Ask Your Doctor
Key Research Papers
Connections

The Big Picture: A Slowable Disease

Chronic kidney disease is usually measured by two numbers: your eGFR (estimated glomerular filtration rate, a stand-in for how much filtering capacity you have left) and your urine albumin-to-creatinine ratio, or UACR (how much protein is leaking into the urine). The goal of everything on this page is to slow the rate at which eGFR falls and to shrink the amount of protein in the urine. Those two changes travel together: less protein leak almost always means slower decline.

A healthy adult loses maybe half a point to one point of eGFR per year, simply from aging. In untreated diabetic or hypertensive kidney disease, that loss can accelerate to four, five, or even ten points per year — a pace that turns a stage-3 kidney into dialysis within a decade. The modern toolkit aims to drag that rate back down toward the normal aging line. When it works well, someone diagnosed at stage 3 in their sixties may keep enough function for the rest of their life.

The strategy is built in layers, and the layers add on top of each other rather than replacing one another. The foundation is blood pressure control and RAAS blockade (ACE inhibitors or ARBs). On top of that sit the newer pillars: SGLT2 inhibitors for almost everyone with CKD, finerenone for people with diabetic kidney disease, and increasingly GLP-1 receptor agonists. Around all of it is the supportive work: correcting acidosis, anemia, and bone disease, and protecting the kidney from things that injure it. No single item is a cure. Stacked together, they are the difference between the old era and this one.

Blood Pressure Control: The Foundation

High blood pressure both causes kidney disease and is caused by it, creating a vicious circle. Each heartbeat pushes blood through the kidney's million tiny filters (glomeruli); when the pressure is too high, those delicate filters are battered, scar over, and drop out of service. Lowering the pressure protects them. This is the single most cost-effective thing most people can do for their kidneys.

How low should you go? The landmark SPRINT trial randomized high-risk adults to a systolic target below 120 versus the older target below 140. The intensive group had about 25% fewer heart attacks, strokes, and heart-failure events and about 27% lower overall death. On the strength of that and later evidence, current kidney guidelines suggest aiming for a systolic pressure under about 120 for most people with CKD, when it can be reached safely. There is an important asterisk: SPRINT measured blood pressure with an automated machine while the patient sat quietly alone, which tends to read several points lower than a rushed cuff in a busy clinic. In everyday practice many clinicians translate that into a home-monitoring target closer to under 130. The exact number should be individualized — frail or older patients, or those who feel dizzy on standing, may do better with a gentler goal.

Measure it at home. A single clinic reading is a snapshot in a stressful moment. An inexpensive validated upper-arm cuff, used morning and evening for a week, gives your doctor a far truer picture and lets you both see whether a medication change is actually working. Sit with your back supported and feet flat, rest five minutes first, and take two readings a minute apart. Bring the log to appointments. Pair blood-pressure work with the sodium limits described on the Kidney-Friendly Diet page — cutting salt below roughly 2,000 mg a day can lower systolic pressure about as much as adding a second pill.

RAAS Blockade: ACE Inhibitors & ARBs

The renin-angiotensin-aldosterone system (RAAS) is the body's blood-pressure and salt-balance thermostat. In kidney disease it gets stuck in the "on" position, clamping down the tiny vessel that drains each filter (the efferent arteriole) and driving the pressure inside the glomerulus dangerously high. Two drug classes release that clamp: ACE inhibitors (names ending in "-pril," such as lisinopril, ramipril, enalapril) and ARBs (names ending in "-sartan," such as losartan, valsartan, irbesartan). By relaxing the outflow vessel, they lower the internal glomerular pressure, and that is why they cut protein leak so effectively — often by a third or more — and slow decline beyond what their blood-pressure effect alone would predict.

The evidence here is old and rock-solid. In the RENAAL trial, losartan reduced the risk of doubling of creatinine, kidney failure, or death by about 16% in people with diabetic kidney disease; in the IDNT trial, irbesartan cut the same kind of composite by roughly 20% versus placebo. These trials from 2001 established RAAS blockade as the backbone of kidney protection, and it remains so today.

Two practical points matter enormously:

Do not double up. It is tempting to think that if one RAAS drug helps, taking an ACE inhibitor and an ARB together would help more. It does not — trials that combined them found more kidney injury, dangerously high potassium, and no added benefit. The rule is one RAAS agent at the right dose, not two.
Expect a small creatinine bump. When you start or increase one of these drugs, your creatinine may rise a little and eGFR dip slightly (up to about 30% from baseline is generally acceptable). That is the drug doing its job — lowering the pressure inside the filter — not damaging the kidney. Your doctor will check a blood test one to two weeks after any change to confirm the potassium is safe and the shift has leveled off.

Because these drugs can raise potassium, people on them need periodic monitoring, and in advanced CKD may need dietary potassium limits. But for anyone with protein in the urine, a RAAS blocker is very often the first medicine started.

SGLT2 Inhibitors: The Game-Changer

If one development deserves the word "revolution" in kidney care, it is the SGLT2 inhibitors — the "-flozin" drugs, chiefly dapagliflozin and empagliflozin (and canagliflozin). They were invented as diabetes pills: they block a transporter in the kidney tubule so that excess glucose is dumped into the urine instead of reabsorbed. Almost by accident, researchers discovered they do something far more valuable — they protect the kidney itself, and the heart along with it.

They work even if you do not have diabetes. This is the part that surprises people. In the DAPA-CKD trial, dapagliflozin reduced the risk of serious kidney decline, kidney failure, or death by nearly 40%, and about a third of the participants had no diabetes at all. The EMPA-KIDNEY trial went further, enrolling a broad CKD population — roughly half of them without diabetes — and still showed empagliflozin cut kidney-disease progression or cardiovascular death by about 28%. The earlier CREDENCE trial had already proven the point in diabetic kidney disease with canagliflozin (about a 30% reduction). A large collaborative meta-analysis pooling these trials confirmed that the kidney benefit holds whether or not you have diabetes. Because of this, dapagliflozin and empagliflozin are now approved specifically to treat CKD, not just diabetes.

The expected eGFR "dip" — the good-news-that-looks-like-bad-news. Here is the single most important thing to understand before you start one of these drugs. In the first few weeks, your eGFR will usually drop a little — often 3 to 5 points, sometimes more. On paper that looks like your kidneys got worse. They did not. The drug works by easing the pressure inside the filters (much like an ACE inhibitor does), and lower internal pressure temporarily shows up as a lower eGFR reading. This dip is expected, harmless, and actually the signature that the protection has switched on. It plateaus within about a month, and from then on your eGFR declines more slowly than it would have — the lines cross, and within a year or two you are better off than if you had never started. Do not stop the drug because of the dip. Your clinician plans for it, checks a follow-up blood test, and only reconsiders if the drop is unusually large (more than about 30%) or you feel unwell.

SGLT2 inhibitors are generally very well tolerated. The main things to know: they cause a modest increase in genital yeast infections (good hygiene helps), they mildly increase urination and thirst at first, and they are on the "hold when you are sick" list described further down. A rare but serious risk is diabetic ketoacidosis, which is why anyone with diabetes should know the warning signs. For the great majority of people with CKD, the benefit dwarfs these concerns.

Finerenone: A New Kind of Protection

Aldosterone is a hormone that promotes salt retention, inflammation, and scarring (fibrosis) in the kidney and heart. Older drugs that block it — spironolactone and eplerenone, the "steroidal" mineralocorticoid receptor antagonists — work but tend to raise potassium sharply and cause side effects like breast tenderness. Finerenone is a newer, non-steroidal blocker of the same receptor, designed to hit the inflammation-and-scarring pathway harder while being gentler elsewhere.

It has been studied specifically in diabetic kidney disease. In FIDELIO-DKD, finerenone reduced the kidney-outcome composite (major eGFR loss, kidney failure, or kidney death) by about 18%. Its companion trial FIGARO-DKD focused on heart outcomes and showed a reduction in cardiovascular events. When the two trials were pooled in the FIDELITY analysis, the drug clearly protected both kidney and heart. Importantly, these benefits came on top of a RAAS blocker — finerenone is an additional layer, not a replacement for your "-pril" or "-sartan."

The main caution is high potassium. Finerenone raises potassium less than the older steroidal drugs, but the risk is real, so it is started at a dose based on your kidney function and potassium level, and your blood is rechecked about four weeks later and periodically after. It is not for people who already run high on potassium. For someone with type 2 diabetes, albuminuria, and residual risk despite a RAAS blocker and an SGLT2 inhibitor, finerenone is often the logical third pillar.

GLP-1 Receptor Agonists: The Newest Evidence

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), liraglutide, dulaglutide, and the dual-agonist tirzepatide — became famous for diabetes and weight loss. They now have direct kidney evidence too. The FLOW trial, published in 2024, was the first study designed specifically to test whether a GLP-1 drug protects the kidneys. In people with type 2 diabetes and CKD, semaglutide reduced the risk of major kidney events (including kidney failure and death) by about 24%, and the trial was stopped early because the benefit was so clear.

How these drugs help the kidney is still being worked out, but it is more than just lower blood sugar: they reduce weight, blood pressure, and inflammation, and appear to have effects on the kidney beyond those. For someone with type 2 diabetes and CKD who is also carrying extra weight, a GLP-1 agonist can address several problems at once. The common side effects are gastrointestinal — nausea, and sometimes vomiting or diarrhea, especially when the dose is going up — which matters here because dehydration from those symptoms is itself hard on the kidneys (see the sick-day rules below). Starting low and increasing slowly minimizes this. As with the other newer agents, GLP-1 drugs stack on top of RAAS blockade and SGLT2 inhibition rather than replacing them; guidelines increasingly describe a "pillar" approach where several of these medicines are used together in the highest-risk patients.

Fixing the Downstream Problems

As kidney function falls, a set of predictable secondary problems appears. Treating them does not just make you feel better — several of them, left alone, speed the decline further, so fixing them is part of slowing progression.

Metabolic acidosis. Failing kidneys struggle to clear the acid produced by normal metabolism, so acid builds up in the blood (a low serum bicarbonate). Chronic acidosis breaks down muscle, weakens bone, and appears to accelerate kidney decline itself. The fix is often simple: oral sodium bicarbonate (baking-soda tablets) to keep the bicarbonate level at or above about 22 mmol/L. In a well-known trial by de Brito-Ashurst and colleagues, bicarbonate supplementation dramatically slowed CKD progression and improved patients' nutrition and muscle mass. Eating more fruits and vegetables (an alkaline load) helps too, balanced carefully against potassium in later stages.

Anemia. Healthy kidneys make erythropoietin, the hormone that tells the bone marrow to build red blood cells. Damaged kidneys make less of it, so many people with CKD become anemic — tired, breathless, foggy. Treatment starts with making sure iron stores are adequate (often iron infusions), and may add an erythropoiesis-stimulating agent or one of the newer oral HIF-PH inhibitors. The goal is to relieve symptoms without pushing the hemoglobin too high, which carries its own risks.

CKD–mineral and bone disease (CKD-MBD). The kidney activates vitamin D and clears phosphorus. As it fails, phosphorus rises, active vitamin D falls, and the parathyroid glands overwork — a cascade that weakens bones and calcifies blood vessels. Management includes limiting phosphorus-heavy processed foods, phosphate-binder medicines taken with meals, active vitamin D or its analogs, and monitoring calcium, phosphorus, and PTH. Magnesium balance also shifts across the stages and should be tracked rather than assumed.

Avoiding Nephrotoxins & Sick-Day Rules

Protecting a kidney is partly about what you add and partly about what you keep away. Several everyday exposures can injure a vulnerable kidney or trigger a sudden drop in function.

NSAIDs. Ibuprofen, naproxen, diclofenac, and similar over-the-counter and prescription pain relievers constrict blood flow into the kidney and are a leading avoidable cause of kidney injury in CKD. Use them rarely, briefly, and only with your clinician's blessing; acetaminophen (paracetamol) is usually the safer choice for everyday aches.
IV contrast dye. The dye used in some CT scans and angiograms can stress the kidneys. It is not forbidden — a needed scan should still be done — but tell every imaging team about your kidney disease so they can hydrate you, use the smallest effective dose, and choose the safest study.
Certain supplements and herbs. "Natural" does not mean kidney-safe. Aristolochic acid (found in some traditional remedies) is directly toxic to kidneys; very high-dose vitamin C can promote oxalate stones; creatine and high-protein powders add filtering load; and some herbal blends are contaminated with heavy metals. High-dose turmeric/curcumin should not be combined with blood thinners. Star fruit is genuinely dangerous in kidney disease and should be avoided. Always show your nephrologist the actual bottles of everything you take.

Sick-day rules. When you have an illness that dehydrates you — vomiting, diarrhea, high fever, or simply not being able to drink — several of your usual medicines can turn from helpful to harmful, because they were designed for a normally hydrated body. The common memory aid is "SADMANS": Sulfonylureas, ACE inhibitors, Diuretics (water pills), Metformin, ARBs, NSAIDs, and SGLT2 inhibitors. During a dehydrating illness, the general advice is to hold these medicines temporarily and restart them once you are eating and drinking normally again for a day or so. Blood-pressure and heart medicines outside this list are usually continued — so ask your own doctor to write you a personalized sick-day plan rather than guessing. Regarding metformin specifically: it is safe for most people down to an eGFR of 30, should not be newly started below 45, is stopped below 30, and is held around contrast scans and acute illness.

Lifestyle: Smoking, Weight & Exercise

The medicines get the headlines, but daily habits move the needle too, and they cost nothing.

Stop smoking. Smoking is an independent accelerator of kidney decline — it damages blood vessels, raises blood pressure, and worsens protein leak. Quitting is one of the highest-value moves a person with CKD can make, and the benefit begins quickly.
Reach a healthier weight. Excess weight drives high blood pressure, diabetes, and inflammation, and forces the remaining nephrons to overwork. Even modest weight loss lowers blood pressure and protein leak. For people with obesity and diabetic CKD, this is one reason GLP-1 agonists are attractive — they help with weight and the kidney at the same time.
Move regularly. Aim for the general target of about 150 minutes a week of moderate activity such as brisk walking, as tolerated. Exercise improves blood pressure, blood sugar, weight, mood, and muscle mass (which acidosis and CKD both erode). It does not need to be strenuous to help.
Eat for your kidneys and your stage. A plant-forward pattern with moderate, individualized protein, limited sodium, and limited ultra-processed food supports everything above. The right potassium and phosphorus targets change as your stage advances, so let your care team and the Kidney-Friendly Diet guidance tailor it — do not blanket-restrict on your own.
Limit alcohol and stay steadily hydrated. Heavy drinking raises blood pressure; aim for water as your default drink rather than either dehydration or forced over-drinking.

What to Ask Your Doctor

Kidney care works best when you are an active partner. Bring this list to your next visit — the answers tell you whether every available layer of protection is switched on for you.

What are my latest eGFR and UACR, and how fast has my eGFR been changing per year? The trend matters more than any single value.
What is my personal blood-pressure target, and should I be monitoring at home?
Am I on an ACE inhibitor or ARB at the maximum dose I can tolerate? (And confirm you are not on both.)
Should I be on an SGLT2 inhibitor — and if I already am, has the expected early eGFR dip been explained and checked?
If I have type 2 diabetes, would I benefit from finerenone and/or a GLP-1 receptor agonist on top of what I already take?
Have we checked for and treated acidosis, anemia, and bone-mineral problems?
Which of my medicines and supplements should I hold when I am sick or dehydrated? Ask for a written sick-day plan.
Are any of my current medicines, supplements, or pain relievers hard on my kidneys?
When should I see a nephrologist if I am not already, and how often should my labs be repeated?

The honest summary: CKD is serious, and none of these tools reverse damage that has already scarred over. But for the first time, a person newly diagnosed with kidney disease has a real, evidence-backed chance of slowing it to a crawl — often enough to keep their own kidneys for the rest of their life. That is a genuinely hopeful change, and it is available now.

Key Research Papers

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). New England Journal of Medicine. 2020;383(15):1436-1446.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). New England Journal of Medicine. 2019;380(24):2295-2306.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease (EMPA-KIDNEY). New England Journal of Medicine. 2023;388(2):117-127.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. 2022;400(10365):1788-1801.
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). New England Journal of Medicine. 2020;383(23):2219-2229.
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes (FIGARO-DKD). New England Journal of Medicine. 2021;385(24):2252-2263.
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022;43(6):474-484.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine. 2024;391(2):109-121.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). New England Journal of Medicine. 2001;345(12):861-869.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). New England Journal of Medicine. 2001;345(12):851-860.
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control (SPRINT). New England Journal of Medicine. 2015;373(22):2103-2116.
de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology. 2009;20(9):2075-2084.
Stevens PE, Ahmed SB, Carrero JJ, et al; KDIGO CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2024;105(4S):S117-S314.

Live PubMed Searches

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents